Pelthos Therapeutics Inc.
ASE: PTHSLive Quote
About Pelthos Therapeutics Inc.
Healthcare
Biotechnology
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
📊 Fundamental Analysis
Pelthos Therapeutics Inc. demonstrates a profit margin of -257.9%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -239.6%, which indicates that capital utilization is currently under pressure.
At a current price of $22.58, PTHS currently sits at the 30th percentile of its 52-week range (Range: $9.00 - $54.29).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$93.49M
Trailing P/E
--
Forward P/E
-215.05
Beta (5Y)
3.99
52W High
$54.29
52W Low
$9.00
Avg Volume
7K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App